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ABSTRACT
As the role of the obstetrician-gynecologist evolves to include primary care, the obstetrician must
assume greater responsibility for providing prenatal preventive care, particularly regarding the
STORCH5 pathogens. (C) 1994 Wiley-Liss, Inc.
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he role of the obstetrician in providing preven-
tive care has been emphasized by the recent
rediscovery by leaders of our specialty that the ob-
stetrician-gynecologist provides primary care. This
new awareness, stimulated by the Clinton health
plan’s emphasis on primary care, is further fueled
by the realization that funding for surgical subspe-
cialty residency slots will be markedly reduced when
any portion of this plan is implemented by Con-
gress into law. A practical result is that, if we
declare ourselves to be generalists, we must take the
responsibility of teaching preventive primary care.
This pre-disease focus for the obstetrician in caring
for the pregnant woman is emphasized in this arti-
cle because the first patient encounter with the ob-
stetrician-gynecologist often occurs when the pa-
tient is already pregnant.
The framework for this discussion of preventive
care in pregnancy is based upon an expansion of the
mnemonic TORCH. Originally, these 5 letters
stood for the first letter of a variety of infectious
agents that cause little or minimal symptomatology
in the pregnant female host, but could have a seri-
ous impact upon the fetus and the newborn. The






This mnemonic was expanded by Gilles Monif
more than a decade ago to STORCH, the German
word for "stork," with the S for Syphilis. In the
early 1990s, Maurice Druzin suggested a new mne-
monic, STORCHs (Table 1). This scheme added
4 new agents with an H in the name title: Hepatitis
B, Human immunodeficiency virus (HIV), Hu-
man papillomavirus (HPV), and Human parvovi-
rus. Human parvovirus is an especially fitting
choice for the fifth H pathogen for it causes fifth
disease in children, which should make it easy to
remember for the practitioners reading this article.
My views presented here may, at times, repre-
sent a deviation from the stands of the American
College of Obstetricians and Gynecologists
(ACOG) as noted in a recent technical bulletin,
but they do represent what I believe is appropriate
preventive care free of either economic or political
considerations.
SYPHILIS
Antepartum testing for syphilis is almost univer-
sally practiced by American obstetricians. I support
this strategy despite the incongruities in the Amer-
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ican philosophy of prevention ofthis organism com-
pared with other known pathogens for the fetus.
For example, syphilis, like toxoplasmosis, is very
uncommon. Until the recent upsurge in congenital
syphilis in urban centers, it was estimated in the
United States to be a less frequent cause of infection
than toxoplasmosis. This low frequency is not a
uniform phenomenon across the country. A re-
markable increase of new cases of congenital syphi-
lis has been noted among the urban poor population
of New York, Florida, Texas, and California.
2
The reappearance of a historical pathogen is part of
a legacy of the trickle-down economics of the Rea-
gan and Bush years of the 1980s and early 1990s in
which there was an increase in the number ofurban
poor, an increase in the homeless population, and a
decrease in federal funding for social services for
these impoverished groups. As a result, there has
been a rise in the incidence of congenital syphilis,
an epidemic spawned, in large part, by the use of
prostitution among urban poor women to support
their cocaine habits. This problem is so frequent
in some urban centers that negative serum samples
for serologic testing for syphilis are diluted to check
for false negatives caused by a prozone phenome-
non due to the high-antigen load.
4 For the average
practitioner dealing with middle-class patients,
syphilis remains an uncommon event and the eval-
uation of a patient with a positive-reagin test, which
is nonspecific, is just as complicated, vague, and
disconcerting as is the antibody testing for women
who are antibody positive for toxoplasmosis. Spe-
cific treponemal antibody testing must be done when
the reagin test is positive to confirm the diagnosis of
syphilis, which is an indication for treatment. I
personally believe that the difference between the
almost universal testing for syphilis among Ameri-
can obstetricians and the rare testing for toxoplas-
mosis is related to medical-school and residency
training, not to practice realities. American physi-
cians understand the intricacies of syphilis testing;
in contrast, they have not been trained in the sero-
logic diagnosis of toxoplasmosis. Rather than main-
tain this unsatisfactory status quo, American physi-
cians should upgrade their knowledge about
toxoplasmosis testing.
There have been treatment changes for the preg-
nant woman suspected of having syphilis. For the
patient with a history of penicillin allergy, penicil-
lin skin testing should be carried out and she should
be given penicillin in increasing doses to reach the
therapeutic levels needed for cure. The older op-
tion of using erythromycin does not effectively treat
the newborn, s Concomitant testing for HIV should
be offered, for HIV-positive women need higher
doses of conventional penicillin, such as procaine
penicillin, 1,200,000 units daily for 10 days, to
avoid the subsequent development of central ner-
vous system (CNS) syphilis.
6 In addition, all preg-
nant women treated for syphilis should be closely
observed at the initiation of treatment for a Jarisch-
Herxheimer reaction, which, if untreated, could




The lack of antepartum testing for this pathogen
remains to me one of the great mysteries of the 20th
century. The reasons American physicians give are
straightforwardly espoused without hesitation. Tox-
oplasmosis is a rare newborn infection, and testing
for it would not be cost effective. This attitude
persists despite the fact that the lowest estimate of
this infection in the newborn is 1.1/1,000 births.
The American obstetrician’s lack of awareness of
the dangers of toxoplasmosis could be related to the
fact that most infections are not apparent at birth
but discovered later by the pediatrician as the child
fails to develop properly. Another reason given for
not testing for toxoplasmosis is that the antibody
testing is uncertain. In addition, an ACOG techni-
cal bulletin suggests that most women with a first
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infection acquired during pregnancy, the danger-
ous one for the fetus, are symptomatic. This obser-
vation implies that testing should be limited to
patients with symptoms, which flies in the face of
most other observations in which only 10% of the
pregnant population acquiring toxoplasmosis will
have symptoms.
Despite the fact that testing for toxoplasmosis is
difficult, it should be offered to the pregnant
woman. If a primary infection is suspected, the
pregnant woman has options that will decrease her
chances of delivering a severely infected newborn.
If an acute infection is discovered early in preg-
nancy, the patient has the choice of pregnancy ter-
mination or treatment with the chemotherapeutic
agents spiramycin and sulfa to lower the overall
incidence of newborn infection and serious CNS
pathology.
9 Those patients who are susceptible, i.e.,
antibody negative, can be given advice that will
lower the risk of acquiring the infection,
1 espe-
cially to avoid the ingestion of raw meat and un-
washed vegetables and intimate contact with hunter
cats. Since asymptomatic latent toxoplasmosis can
become a threat to anyone subsequently acquiring
HIV, such counseling is a worthwhile public-health
endeavor for all women who are antibody negative,
whether they are pregnant or not. The pitfalls of
diagnosing acute toxoplasmosis infection during
pregnancy should be recognized by every Ameri-
can obstetrician. The IgM test for toxoplasmosis,
done in most commercial laboratories, can detect
antibody persisting for long periods, more than
year in some instances.
1 Positive-antibody testing
for toxoplasmosis prior to pregnancy is a distinct
help to the obstetrician. It eliminates the risk to the
fetus during pregnancy and avoids the interpreta-
tion of IgM test results. If pre-pregnancy testing
has not been done for a pregnant patient who is
IgM positive for toxoplasmosis, an amniocentesis
can be performed with either culture or polymerase
chain reaction (PCR) testing for Toxoplasma gon-
dii.
12 This approach is more sensitive than umbili-
cal blood sampling and subsequent testing for IgM
antibody in fetal blood, which are positive in only




Testing for the presence of measles antibody should
be done because it can trigger preventive medical
intervention. Measles (variola) is not a known ter-
atogen, but primary infections in pregnant adults
can induce a higher-than-expected rate of prema-
ture labor and delivery.
13 My concern about mea-
sles was accentuated by the drop in measles immu-
nizations in the United States during the 1980s and
the resulting high number of pregnant women in
the 1990s who are measles susceptible. When iden-
tified by serologic testing, these patients can be
immunized in the postpartum period, for this vac-
cine is a live virus.
Varicella
Testing for varicella should be part of prenatal
care. For the susceptible adult, an acute infection
can cause serious pulmonary infections and even
death.
4 In addition, a fetus occasionally gets in-
fected in utero with CNS and limb defects. The
susceptible pregnant woman exposed to varicella
should receive intravenous (IV) acyclovir if there
are signs or symptoms of pneumonia.
15 Frequent
sonographic studies of the newborn should be done
to detect any fetal abnormalities. In the future,
postpartum susceptible women can be given the
just-released varicella vaccine which is well toler-
ated by adults.
Group B Streptococcus (GBS)
GBS can cause early onset sepsis in the newborn,
with death or CNS damage in survivors of post-
delivery antibiotic treatment. This problem is seen
more frequently in women who deliver premature
babies,
16 and newborn outcome is improved by the
intrapartum administration of antibiotics compared
with postpartum administration.
17 TO address the
issue ofantepartum prophylaxis, the American Col-
lege of Pediatricians has recommended that vaginal
and rectal cultures for GBS be done at 26-28 weeks
gestation, with high-risk patients who are culture
positive at the time of screening being given an-
tepartum antibiotic prophylaxis.
18 These high-risk
patients include women with preterm labor, pre-
mature rupture of the membranes, and prolonged
rupture of the membranes in term births and
women with multiple gestations. I believe this strat-
egy is hopelessly flawed because the GBS coloniza-
tion in pregnant women is a skip phenomenon, not
a constant. Indeed, one longitudinal study of preg-
nant women found that only 51% of those who were
colonized at term had been culture positive when
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screened in the first trimester.
19 This means that
some women treated on the basis of the suggested
midtrimester culture will be culture negative and
some women who are culture negative at 26-28
weeks but culture positive at the time of delivery
will not be treated. At present, the most logical
approach is the one suggested by Minkoff and
Mead: High-risk patients are cultured at the time
of admission. If they go into labor before cultures
are available or if they are culture positive before
labor ensues, they should be treated with antibiotics
prior to delivery. There should be one caveat for
whatever strategy is chosen by obstetricians. Based
upon our current state of knowledge, we cannot
prevent all acute onset GBS infections. Even treat-
ing every patient admitted in labor with antibiotics
may not prevent newborn infection and death.
21
The ultimate answer to this serious newborn prob-
lem will be the development of a protective vaccine
or more rapid, accurate microbiologic screens for
the presence of this organism.
Neisseria gonorrhoeae
N. gonorrhoeae is a pathogen that, in the pregnant
woman, has been associated with premature labor
and delivery.
22 Screening for this pathogen should
be done at the initial obstetrical-care contact. If the
screening test is positive, both the patient and her
male sexual partner should be treated.
Chlamydia trachomatis
The significance of C. trachomatis infection for the
pregnant woman has been questioned. Although
some studies have shown a relationship between
positive cultures and pregnancy complications,
23
other studies have not shown this relationship.
24
Recent studies by Witkin et al.
2s have demon-
strated a broad impact of infection with C. trachom-
at# on reproductive processes. It seems clear from
these sophisticated studies that tubal damage due to
infection with this organism is an autoimmune phe-
nomenon. The human host’s allergic response to
the heat-shock protein of C. trachomat# triggers a
response with subsequent infection with chlamydia
or other genital-tract organisms, in which the body
cannot distinguish between the heat-shock protein
of chlamydia and normal body protein. The result-
ing tubal damage causes infertility
26 or an increased
incidence of tubal pregnancy.
27 Some recent stud-
ies of infertile couples who either conceived natu-
rally
28 or through the in vitro process
29 have shown
an increased rate of abortion. Therefore, as a mini-
mum, first-trimester screening for C. trachomatis
should be done with the most sensitive screening
technique, the PCR,
3 and those patients who are
positive plus their sexual partners should be treated
with either erythromycin or amoxicillin.
1 There is
an additional problem near delivery. Those women
who are carriers of C. trachomatis may infect their
newborns with a resultant conjunctivitis not cured
by local antibiotic preparations. I believe that all
pregnant women should be screened for C. tra-
chomatis in the third trimester and those women




There has been a resurgence of tuberculosis in the
United States in the past decade. The increase in the
number of people living in poverty, the emergence
of a large number of homeless people, and the entry
to the United States of large numbers of immi-
grants from the Caribbean and Southeast Asia with
a high proportion of tuberculosis have increased the
number of pregnant women with active tuberculo-
sis. Among urban poor pregnant patients, a mini-
mum standard should be universal skin testing,
with chest roentgen examination for all those who
are skin-test positive. If the chest X-ray is normal,
these women with no history of treatment or vacci-
nation (BCG, Quad Pharmaceuticals, Inc., India-
napolis, IN) should be treated for a minimum of 6
months with isoniazid (INH, CIBA Pharmaceuti-
cal Company, Summit, NJ).
2 Women with active
pulmonary lesions should be treated with a combi-
nation of systemic agents based upon antibacterial
susceptibility studies. To prevent fetal eighth-nerve
toxicity, aminoglycosides should be avoided.
3
There is an additional problem for physicians plan-
ning tuberculosis screening in pregnancy. A preg-
nant woman with acquired immunodeficiency syn-
drome (AIDS) who has an active tuberculosis
infection can be skin-test negative.
4 A chest X-ray
is the minimum requirement for screening in a
patient who is I-IIV positive. If the HIV-positivity
rate approaches 1% in a pregnant population, I
believe that routine chest X-rays with abdominal
shielding should be done for all prenatal patients.
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RUBELLA
Rubella is the grandfather ofthe STORCH
5 patho-
gens because of the relationship between maternal
infection and newborn abnormalities noted by
Gregg
3s in the 1940s. There were 2 major break-
throughs in the 1960s that markedly lowered the
incidence of newborn infection due to this organ-
ism. The virus was isolated and a vaccine was de-
veloped. Preschool immunization of children in
the United States has resulted in enough herd im-
munity that no epidemics of rubella have been seen
since the clinical introduction of the vaccine. De-
spite this immunization program, not every preg-
nant woman is immune. Ideally, a woman should
be screened before her first pregnancy. If she is
immune, this fact should be noted for any subse-
quent pregnancy. Susceptible women can be im-
munized. For reasons that I do not understand,
adult women have a much higher incidence of ar-
thritic symptoms following rubella immunization
than adult men.
36 All female patients should be
warned of this possibility before receiving the vac-
cine. In most cases, this complication is a transient
problem that is easily treated with antiprostaglan-
dins, although the symptoms may persist for
months. An informed consent with this informa-
tion should be obtained to assure the patient’s knowl-
edge of this possibility.
CYTOMEGALOVIRUS
Cytomegalovirus screening is the source ofmy sec-
ond-biggest bone of contention with the ACOG
technical bulletin, ranking just below toxoplasmo-
sis. I agree with their assessment of the problem.
Cytomegalovirus is the most common cause ofnew-
born infection, infecting nearly 1% of all new-
borns.
7 From here on, we diverge, for the ACOG
technical bulletin states that, since nothing can be
done, no testing should be done. This flies in the
face of reality. It seems clear from prior studies in
Alabama that a pre-pregnancy infection with cy-
tomegalovirus confers some protection to the fetus;
both the number and severity of infections are re-
duced.
8 This information is valuable for the
mother and the obstetrician, and a recent vs. old
infection can be ascertained by serial determina-
tions of IgG and IgM. The cytomegalovirus-sus-
ceptible patient should be counseled by her obstetri-
cian. Hospital nurses in high-risk areas for the
acquisition of cytomegalovirus can markedly re-
duce their rate of cytomegalovirus infection by
washing their hands thoroughly after each patient
encounter.
9 For the susceptible pregnant woman
who is not a nurse, the biggest source of infection is
young children in day-care centers
4 or in school.
These infected children shed virus in their oral
secretions and urine. These susceptible pregnant
mothers-to-be should be advised to avoid kissing
these children and to wash their hands thoroughly
after they change a diaper. Pregnant women can
acquire cytomegalovirus through blood transfu-
sions, so blood banks should use cytomegalovirus-
seronegative blood for women who are suscepti-
ble.
41 Various treatments including vaccines
42 and
acyclovir
4 have been tested in immunosuppressed
nonpregnant patients. Perhaps such interventions
will be tested in pregnant women in the future.
HERPES
Herpes (H )
My thinking about herpes infections in the new-
born has undergone major revisions in the past
decade because of an explosion of new information.
In the past, I focused upon the patient with a his-
tory of genital herpes and used weekly vaginal cul-
tures for herpes from 36 weeks gestation until term
in this population to determine whether vaginal
delivery or cesarean section is indicated.
44 A num-
ber of observations have made me abandon this
strategy. Studies have determined that a primary
infection during pregnancy is much more danger-
ous to the fetus than a recurrent infection;
4s only
10% of women with HSV-2 infection as deter-
mined by positive-antibody status will ever have
any signs or symptoms of a genital herpes infec-
tion;
46 70% of the newborn infections caused by
herpes occur in women who either have no history
ofgenital herpes infection or, ifthey have a history,
are asymptomatic at the time of delivery;
47 and the
weekly genital culture for herpes is not predictive
when the patient returns in labor.
48 Because of
these findings, I no longer do weekly cultures for
herpes near term. I pay close attention to any pa-
tient symptomatology suggesting that a genital
herpes outbreak is about to occur and examine the
patient for genital lesions when she is admitted in
labor. If either symptomatology or lesions are
present, I do an immediate cesarean section. Fi-
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nally, in a patient with a history of genital herpes, I
do not use scalp electrodes, thus avoiding an inva-
sive procedure in a woman who could be shedding
herpes virus asymptomatically.
49 There are case
reports of scalp infections due to the use of invasive
technology
5 and this risk is totally avoidable. Not
every investigator agrees with this stand, but a




The incidence of hepatitis B infection in the United
States has increased markedly in the past decade.
There are a number of obvious contributors to this
alarming trend: an increase in poverty; continued
dissolution of the family unit among the urban
poor, particularly black Americans; an influx of
immigrants from the Caribbean and the Far East
where the incidence of infection with this virus is
high; increased sexual contacts without the use of
barrier contraceptives, for it is a sexually transmit-
ted disease; and the sharing of needles among IV
drug users. This increase in the incidence of hepa-
titis B infections in the United States has been
accompanied by an increase in hepatitis B infection
in the newborns ofwomen who are antigen positive
for hepatitis B. An early strategy is to restrict screen-
ing to high-risk mothers in an effort to lower health-
care costs. Articles still appear in our literature
evaluating the cost effectiveness of universal screen-
ing for the hepatitis B antigen. The fact of the
matter is that restricting screening to high-risk pa-
tients means that a good number of hepatitis B
antigen-positive mothers will be missed. Since an-
tepartum detection and postpartum treatment of the
newborn with hepatitis B immune globulin and
hepatitis B vaccine largely eliminate newborn in-
fection
s2 and avoid subsequent cirrhosis and liver
cancer, the choice to me is clear. There should be
universal antepartum screening for the hepatitis B
antigen. Susceptible patients can be immunized
postpartum.
HIV (H)
Screening for the presence of t-tIV antibody has
been politicized in this country. As a result, it is
hard to determine appropriate medical policy be-
cause the incidence of infection is unknown and
patients can refuse to have testing. For the obstetri-
cian practicing in Massachusetts, important anony-
mous data are available. All cord bloods are tested
anonymously for HIV antibodies, which gives the
obstetrician important baseline data. This informa-
tion makes it possible to know the incidence of
maternal HIV antibody-positive women in the ob-
stetrical population for a given time frame. There
are major differences in frequency, with a higher
incidence seen in inner-city hospitals than in rural
areas,
s3 In addition, I have been impressed that, on
our own obstetrical service at the New York Hospi-
tal, only half of the HIV-positive women discov-
ered by anonymous cord-blood sampling have been
identified by obstetricians in assessing the high-risk
activity of patients. For this reason, I would stress
widespread testing in any obstetrical population in
which the positive HIV-antibody incidence nears
or exceeds 1%. How do you convince women to be
tested? Although newborn infection with HIV
ranges from 20 to 60% in some studies,
s4 the
knowledge of a positive HIV-antibody test infre-
quently results in a decision to terminate the preg-
nancy in these urban poor women. Instead, preven-
tion measures can be stressed. These patients may
be candidates for zidovudine (AZT) prophylaxis
during pregnancy and should be screened for Pneu-
mocystis carinii pneumonia, tuberculosis, and syph-
ilis. A recent study suggests that AZT prophylaxis
in pregnancy lowers the risk of I-IIV acquisition by
the newborn.
55 In addition, appropriately directed
antibiotic therapy should increase their number of
symptom-free days. The knowledge that a pregnant
woman is HIV-antibody positive should influence
intrapartum management. Since some of these
women will shed HIV in their vaginal secretions, a
fetal scalp electrode and fetal scalp sampling should
not be employed because either procedure breaks
the skin barrier and exposes the newborn to infec-
tion.
HPV (H)
Obstetricians are at an early phase on the learning
curve of an appropriate response to HPV infec-
tions. Some important bits of information are avail-
able. One study of sexually active female college
undergraduates, using a PCR technique, found that
46% had been exposed and infected with this family
of viruses, s6 In addition, some strains of this virus
have been associated with an increased incidence of
cervical carcinoma, s7 The virus has not been grown
in clinical-laboratory tissue cultures, and identifi-
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cation to date has been dependent upon pathologic
tissue changes and detection of DNA for certain
strains ofHPV. The pathologic interpretation var-
ies among pathologists, and the DNA probe is lim-
ited to a small number of HPV strains. A confir-
mation of the presence of the virus in cervical tissue
usually leads to some type of ablative procedure
postpartum. Papillomatosis of the vocal cords of
newbor.ns has been reported. Fortunately, this com-
plication has been a rare event in newborns and no
studies have indicated that cesarean sections should
be performed in such women.
Human Parvovirus (Hs)
An acute infection with this virus can cause intra-
vascular hemolysis. In the fetus, the subsequent
anemia can cause nonimmune hydrops which, if
untreated, can result in fetal death, s8 Fortunately,
maternal infections with human parvovirus are rare
and few susceptible newborns develop intrauterine
anemia.
59 For the few affected fetuses, a diagnosis
of intrauterine anemia can be made by intrauterine
fetal blood sampling, and these anemic infants can
be effectively treated with intrauterine blood trans-
fusions.
CONCLUSIONS
This overview of scientific preventive care for the
pregnant woman is free of any political consider-
ations. As advocates for the best care for women,
we should endorse all of these prenatal preventive
measures and put them into practice.
REFERENCES
1. American College of Obstetricians and Gynecologists:
Perinatal viral and parasitic infection. Tech Bull 177:
1-7, 1993.
2. Centers for Disease Control: Congenital syphilismUnited
States, 1985-85. JAMA 256:3206-3208, 1986.
3. Centers for Disease Control: Relationship of syphilis to
drug use and prostitution--Connecticut and Philadelphia,
Pennsylvania. MMWR 37:755-764, 1988.
4. Berkowitz KM, Stampf K, Baxi L, et al.: False negative
screening tests for syphilis in pregnant women. N Engl J
Med 322:270-271, 1990.
5. Centers for Disease Control: Guidelines for the preven-
tion and control of congenital syphilis. MMWR 37:S1-
S13, 1988.
6. Musher DM: Syphilis, neurosyphilis, penicillin, and
AIDS. J Infect Dis 163:1201-1206, 1991.
7. Kelin VR, Cox SM, Mitchell MD, et al.: The Jarisch-
I-Ierxheimer reaction complicating syphilotherapy in preg-
nancy. Obstet Gynecol 75:375-380, 1990.
8. Wilson CB, Remington JS: What can be done to prevent
congenital toxoplasmosis? Am J Obstet Gynecol 138:357-
363, 1980.
9. Daffos F, Foreister F, Gapella-Paulovsky M, et al.: Pre-
natal management of 746 pregnancies at risk for congeni-
tal toxoplasmosis. N Engl J Med 318:271-275, 1988.
10. Foulon W, Naessens A, Lauwers S, et al.: Impact of
primary prevention on the incidence oftoxoplasmosis dur-
ing pregnancy. Obstet Gynecol 72:363-366, 1988.
11. Brooks RG, McCabe RE, Remington JS: Role of serol-
ogy in the diagnosis of toxoplasmosis lymphadenopathy.
Rev Infect Dis 9:755-782, 1987.
12. Groover CM, Thulliez P, Remington JS, et al.: Rapid
prenatal diagnosis of congenital toxoplasma infection by
using polymerase chain reaction and amniotic fluid. J
Clin Microbiol 28:2297-2301, 1990.
13. Siegel M, Fuerst HT: Low birthweight and maternal
viral diseases. A progressive study of rubella, measles,
mumps, chickenpox, and hepatitis. JAMA 197:680-684,
1966.
14. Balducci J, Rodis JF, Rosengren S, et al.: Pregnancy
outcomes following first-trimester varicella infection. Ob-
stet Gynecol 79:5-6, 1992.
15. Smego RA Jr, Asperilla MO: Use of acyclovir for vari-
cella pneumonia during pregnancy. Obstet Gynecol 78:
1112-1116, 1991.
16. Baker CJ, Barrett FF: Transmission of group B strepto-
cocci among parturient women and their neonates. J Pedi-
atr 83:919-923, 1973.
17. Pyati SP, Pildes RS, Jacobs NM, et al.: Penicillin in
infants weighing two kilograms or less with early onset
group B streptococcal disease. N Engl J Med 308:1383-
1389, 1983.
18. Committee on Infectious Diseases in Fetus and Newborn:
Guidelines for prevention ofgroup B streptococcal (CBS)
infection by chemoprophylaxis. Pediatrics 90:775-778,
1992.
19. Lewin EB, Amstey MS: Natural history ofgroup B strep-
tococcus colonization and its therapy during pregnancy.
Am J Obstet Gynecol 139:512-515, 1981.
20. Minkoff H, Mead P: An obstetric approach to the pre-
vention of early onset group B ]3-hemolytic streptococcal
sepsis. Am J Obstet Gynecol 154:973-977, 1986.
21. Hamoudi AC, Hamoudi AB: Fetal group B streptococcal
pneumonia in neonates. Effects of antibiotics. Am J Clin
Pathol 76:823-826, 1981.
22. Handsfield HI-I, Hudson WA, Holmes KK: Neonatal
gonococcal infection. JAMA 225:697-701, 1973.
23. Martin DH, Koutsky L, Eschenbach DA, et al.: Prema-
turity and perinatal mortality in pregnancies complicated
by maternal Chlamydia trachomatis infections. JAMA 247:
1585-1588, 1982.
24. Harrison HR, Alexander ER, Weinstein L, et al.: Cer-
vical Chlamydia trachomatis and mycoplasmal infections
in pregnancy. JAMA 250:1721-1727, 1983.
25. Witkin SS, Jeremias J, Toth M, et al.: Cell mediated
immune response to the recombinant 57-kDa heat shock
protein of Chlamydia trachomatis in women with salpingi-
tis. J Infect Dis 167:1379-1383, 1993.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYPREVENTIVE ANTEPARTUM CARE LEDGER
26. Brunham RC, McLean IW, Binns B, et al.: Chlamydia
trachomatis: Its role in tubal infertility. J Infect Dis 152:
1275-1282, 1985.
27. Brunham RC, Binns B, McDowell J, et al.: Chlamydia
trachomatis infection in women with ectopic pregnancy.
Obstet Gynecol 67:722-726, 1986.
28. Witkin SS, Ledger WJ: Antibodies to Chlamydia tra-
chomatis in sera of women with recurrent spontaneous
abortion. Am J Obstet Gynecol 167:135-139, 1992.
29. Licciardi F, Grifo JA, Rosenwaks Z, et al.: Relation
between antibodies to Chlamydia trachomatis and sponta-
neous abortion following in vitro fertilization. J Assist
Reprod 9:207-210, 1992.
30. Witkin SS, Jeremias j, Toth M, et al.: Detection of
Chlamydia trachomatis by the polymerase chain reaction in
the cervices ofwomen with acute salpingitis. Am J Obstet
Gynecol 168:1438-1442, 1993.
31. Cromblehome WR, Schacter J, Grossman M, et al.:
Amoxicillin therapy for Chlamydia trachomatis in preg-
nancy. Obstet Gynecol 75:752-756, 1990.
32. Snider DE: Pregnancy and tuberculosis. Chest 86:10S-
13S, 1984.
33. Glassroth J, Rubins AG, Snider DE Jr: Tuberculosis in
the 1980s. N EnglJ Med 302:1441-1450, 1980.
34. Pitchenik AE, Fertel D, Blocker AB: Mycobacterial dis-
ease: Epidemiology, diagnosis, treatment, and preven-
tion. Clin Chest Med 9:425-441, 1988.
35. Gregg NM: Congenital cataract following German mea-
sles in the mother. Trans Aust Coll Ophthalmol 3:35-39,
1941.
36. Howson CP, Katz M, Johnston RB Jr, et al.: Chronic
arthritis after rubella vaccination. Clin Infect Dis 15:
307-312, 1992.
37. Yow MD, Demmler GJ: Congenital cytomegalovirus dis-
ease--20 years is long enough. N Engl J Med 326:702-
703, 1992.
38. Fowler KB, Stagno S, Pass RF, et al.: The outcome of
congenital cytomegalovirus infection in relation to mater-
nal antibody status. N Engl J Med 326:663-667, 1992.
39. Balfour CL, Balfour HH Jr: Cytomegalovirus is not an
occupational risk for nurses in renal transport and neona-
tal units: Results of a prospective surveillance study.
JAMA 256:1909-1914, 1986.
40. Murph JR, Baron JC, Brown CK, et al.: The occupa-
tional risk of cytomegalovirus infection among day-care
providers. JAMA 265:603-608, 1991.
41. Bowden RA, Sayers M, Flournoy N, et al.: Cytomegalo-
virus immunoglobulin and seronegative blood products to
prevent primary cytomegalovirus infection after marrow
transplant. N Engl J Med 314:1006-1010, 1986.
42. Plotkin SA, Starr SE, Friedman HM, et al.: Effect of
Towne live vaccine on cytomegalovirus disease in patients
receiving renal transplants. Ann Intern Med 114:525-
531, 1991.
43. Balfour HH, Chace BA, Stapleton JJ, et al.: A random-
ized placeob-controlled trial of oral acyclovir in recipients
of renal allografts. N EnglJ Med 320;1381-1387, 1990.
44. Grossman I-IJ III, Wallen WC, Sever JL: Management
of the herpes simplex virus during pregnancy. Obstet
Gynecol 58:1-4, 1981.
45. Brown ZA, Vontuer LA, Benedetti J, et al.: Effects on
infants of a first episode of genital herpes during preg-
nancy. N EnglJ Med 317:1246-1251, 1987.
46. Breinig MK, Kingsley LA, Armstrong JA, et al.: Epide-
miology of genital herpes in Pittsburgh: Serologic, sex-
ual, and racial correlates ofapparent and inapparent herpes
simplex infections. J Infect Dis 162:299-305, 1990.
47. Whitley RJ, Corey L, Arvin A, et al.: Changing presen-
tation of herpes simplex virus infection in neonates. J
Infect Dis 158:109-116, 1988.
48. Prober CG, Hensleigh PA, Boucher FD, et al.: Use of
routine viral cultures at delivery to identify neonates ex-
posed to herpes simplex virus. N Engl J Med 318:887-
891, 1988.
49. Ledger WJ: Neonatal herpes simplex infection. N Engl J
Med 319:872, 1988.
50. Whitley RJ, Nahmias AJ, Visuntine AM, et al.: The
natural history of herpes simplex virus infection ofmother
and newborn. Pediatrics 66:489-494, 1980.
51. Eason E, Banjamin A: Preventing neonatal herpes. N
Engl J Med 327:647-648, 1992.
52. Immunization Practices Advisory Committee: Recom-
mendations for protection against viral hepatitis. MMWR
34:313-335, 1985.
53. Hoff R, Berandi VP, Weiblen BJ, et al.: Seroprevalence
of human immunodeficiency virus among childbearing
women. N EnglJ Med 318:525-530, 1988.
54. Lindsay MK, Peterson HB, Feng TI, et al.: Routine
antepartum human immunodeficiency virus infection
screening in an inner city population. Obstet Gynecol
74:289-294, 1989.
55. National Institutes of Health: NIH Clinical Alert, 1994.
56. Bauer I-IM, Ting Y, Greet CE, et al.: Genital human
papillomavirus infection in female university students as
determined by a PCR-based method. JAMA 265:472-
477, 1991.
57. Reeves WC, Brinton LA, Garcia M, et al.: Human
papillomavirus infection and cervical cancer in Latin
America. N Engl J Med 320:1437-1441, 1989.
58. Peters MT, Nicolaides HK: Cordocentesis for the diag-
nosis and treatment of human fetal parvovirus infection.
Obstet Gynecol 75:501-504, 1990.
59. Boden E, Eriksson A, Rylander E, et al.: Clinical charac-
teristics of papillomavirus vulvovaginitis. Acta Obstet
Gynecol Scand 67:147-151, 1988.
90 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY